Spasmofree indications
Treatment of enteritis; treatment of Pneumocystis carinii pneumonia; treatment of severe or complicated UTIs caused by susceptible strains of bacteria.
-Treatment of acute otitis media and acute exacerbations of chronic bronchitis; treatment of traveler’s diarrhea; treatment and prophylaxis of P. carinii pneumonia; Shigella enteritis; UTIs caused by susceptible strains of bacteria.
-Treatment of cholera, salmonella-type infections, and nocardiosis; prevention of recurrent UTIs in women; prophylaxis of bacterial infections in susceptible patients; treatment of acute and chronic bacterial prostatitis; treatment of skin and soft-tissue infections caused by Staphylococcus aureus.
Spasmofree interactions
ACE inhibitors
Hyperkalemia, possibly with cardiac arrhythmias or cardiac arrest, may occur during coadministration.
Amantadine
A case of toxic delirium has been reported after coadministration with sulfamethoxazole/trimethoprim.
Antiarrhythmic agents (eg, amiodarone, bretylium, disopyramide, dofetilide, procainamide, quinidine, sotalol), arsenic trioxide, chlorpromazine, cisapride, dolasetron, droperidol, mefloquine, mesoridazine, moxifloxacin, pentamidine, pimozide, tacrolimus, thioridazine, ziprasidone
An additive effect of trimethoprim/sulfamethoxazole with other drugs that prolong the QT interval cannot be excluded.
Cyclosporine
May cause decreased therapeutic effect of cyclosporine and increased risk of nephrotoxicity.
Digoxin
Increased digoxin levels may occur.
Diuretics (eg, thiazides)
An increased incidence of thrombocytopenia with purpura has been reported during coadministration.
Indomethacin
Sulfamethoxazole blood levels may be increased.
Methenamine
Methenamine is contraindicated for use with sulfonamides because of the potential of formation of insoluble precipitates in the urine.
Methotrexate
May displace methotrexate from protein-binding sites, thus increasing free methotrexate levels.
Phenytoin
Trimethoprim may inhibit metabolism of phenytoin or other hydantoins.
Procainamide
Trimethoprim may inhibit renal elimination of procainamide and its metabolites.
Sulfones (eg, dapsone)
The plasma concentration of both drugs may be increased.
Sulfonylureas
May increase hypoglycemic response to sulfonylureas because of displacement from protein-binding sites or inhibition of hepatic metabolism.
Tricyclic antidepressants
Efficacy may be decreased.
Vaccines, live
The effectiveness of live vaccines may be decreased.
Warfarin
May cause prolonged PT.
Laboratory Test Interactions
Can interfere with serum methotrexate assay as determined by competitive binding protein technique when bacterial dihydrofolate reductase is used as binding protein. May interfere with Jaffe alkaline picrate reaction assay for creatinine, resulting in overestimations
Spasmofree side effects
CNS
Apathy, aseptic meningitis, ataxia, convulsions, depression, fatigue, hallucinations, headache, insomnia, nervousness, peripheral neuritis, vertigo, weakness.
EENT
Tinnitus.
Endocrine
Diuresis, hypoglycemia.
Hematologic
Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, hypoprothrombinemia, leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia.
Hypersensitivity
Allergic myocarditis, anaphylaxis, angioedema, chills, conjunctival and scleral injection, drug fever, erythema multiforme, exfoliative dermatitis, generalized allergic reactions, generalized skin eruptions, Henoch-Schoenlein purpura, periarteritis nodosa, photosensitivity, pruritus, rash, serum sickness–like syndrome, Stevens-Johnson syndrome, systemic lupus erythematosus, toxic epidermal necrolysis, urticaria.
GI
Abdominal pain, anorexia, diarrhea, elevation of serum transaminase and bilirubin, emesis, glossitis, hepatitis (including cholestatic jaundice and hepatic necrosis), nausea, pancreatitis, pseudomembranous enterocolitis, stomatitis, vomiting.
Genitourinary
BUN and serum creatinine elevation, crystalluria and nephrotoxicity in association with cyclosporine, interstitial nephritis, renal failure, toxic nephrosis with oliguria and anuria.
Metabolic
Hyperkalemia.
Musculoskeletal
Arthralgia, myalgia, rhabdomyolysis.
Respiratory
Cough, pulmonary infiltrates, shortness of breath.
Spasmofree contraindications
Trimethoprim is contraindicated in individuals hypersensitive to trimethoprim and in those with documented megaloblastic anemia due to folate deficiency.
Active ingredient matches for Spasmofree:
Tiemonium Methylsulfate in Egypt.
List of Spasmofree substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Spasalgin (Bangladesh) | |
| Tiemonium Methylsulfate (Algeria) | |
| Timem (Bangladesh) | |
| Timeth (Bangladesh) | |
| Timo (Bangladesh) | |
| Timoben (Bangladesh) | |
| Timonac (Bangladesh) | |
| Timonal (Algeria) | |
| Timothy (Bangladesh) | |
| Timozin (Bangladesh) | |
| Tinium (Bangladesh) | |
| Tino (Bangladesh) | |
| Tisu (Bangladesh) | |
| Titos (Bangladesh) | |
| TMS (Bangladesh) | |
| TMS 15 ml Syrup (Biocare Remedies) | $ 0.15 |
| Tynium (Bangladesh) | |
| Viscer (Bangladesh) | |
| Viscera (Egypt) | |
| Visceral (Bangladesh) | |
| Visceralgin (Australia) | |
| Tablet, Film-Coated; Oral; Tiemonium Methylsulfate 50 mg (Fawns & mcallan) | |
| Visceralgina (Italy) | |
| Tablet, Film-Coated; Oral; Tiemonium Methylsulfate 50 mg (Sit) | |
| Visceralgine (Bangladesh, Indonesia, Japan, Luxembourg, Tunisia) | |
| Tablet, Film-Coated; Oral; Tiemonium Methylsulfate 50 mg (Exel) | |
| Visceralgine 30 Tablet (Exel) | |
| Visceralgine 2 mL x 10 tube (Exel) | |
| Visceralgine 10 mg/5 mL x 100 mL x 1's (Exel) | $ 10.22 |
| Visceralgine 50 mg x 30 Tablet (Exel) | |
| Visceralgine 5 mg/2 mL x 10 tube (Exel) | |
| Viscéralgine (France) | |
| Tablet, Film-Coated; Oral; Tiemonium Methylsulfate 50 mg | |
| Visceralgine 30 Tablet | |
| Visceralgine 2 mL x 10 tube | |
| Visceralgine 10 mg/5 mL x 100 mL x 1's | $ 10.22 |
| Visceralgine 50 mg x 30 Tablet | |
| Visceralgine 5 mg/2 mL x 10 tube | |
| Tablet, Film-Coated; Oral; Tiemonium Methylsulfate 50 mg | |
| Visceralgine 30 Tablet | |
| Visceralgine 2 mL x 10 tube | |
| Visceralgine 10 mg/5 mL x 100 mL x 1's | $ 10.22 |
| Visceralgine 50 mg x 30 Tablet | |
| Visceralgine 5 mg/2 mL x 10 tube | |
| Visegin (Bangladesh) | |
| Viset (Bangladesh) | |
| Visnor (Bangladesh) | |
See 59 substitutes for Spasmofree | |
Reviews
The results of a survey conducted on ndrugs.com for Spasmofree are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Spasmofree. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Spasmofree drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 1 | 100.0% | |
Consumer reported price estimates
No survey data has been collected yet3 consumers reported time for results
To what extent do I have to use Spasmofree before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Spasmofree. To get the time effectiveness of using Spasmofree drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 day | 2 | 66.7% | |
| 5 days | 1 | 33.3% | |
14 consumers reported age
| Users | % | ||
|---|---|---|---|
| 16-29 | 5 | 35.7% | |
| 30-45 | 4 | 28.6% | |
| 6-15 | 3 | 21.4% | |
| > 60 | 1 | 7.1% | |
| 1-5 | 1 | 7.1% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
